🎉 M&A multiples are live!
Check it out!

Cellectar Biosciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Cellectar Biosciences and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Cellectar Biosciences Overview

About Cellectar Biosciences

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.


Founded

1996

HQ

United States of America
Employees

11

Website

cellectar.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

-$8.7M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Cellectar Biosciences Financials

Cellectar Biosciences has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Cellectar Biosciences achieved revenue of n/a and an EBITDA of -$51.5M.

Cellectar Biosciences expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Cellectar Biosciences valuation multiples based on analyst estimates

Cellectar Biosciences P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$38.8M -$51.5M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$28.6M -$38.0M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Cellectar Biosciences Stock Performance

As of April 15, 2025, Cellectar Biosciences's stock price is $0.

Cellectar Biosciences has current market cap of $13.6M, and EV of -$8.7M.

See Cellectar Biosciences trading valuation data

Cellectar Biosciences Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$8.7M $13.6M XXX XXX XXX XXX $-1.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Cellectar Biosciences Valuation Multiples

As of April 15, 2025, Cellectar Biosciences has market cap of $13.6M and EV of -$8.7M.

Cellectar Biosciences's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Cellectar Biosciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Cellectar Biosciences and 10K+ public comps

Cellectar Biosciences Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$8.7M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 0.2x XXX XXX XXX
P/E -0.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Cellectar Biosciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Cellectar Biosciences Valuation Multiples

Cellectar Biosciences's NTM/LTM revenue growth is n/a

Cellectar Biosciences's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $4.7M for the same period.

Over next 12 months, Cellectar Biosciences's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Cellectar Biosciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Cellectar Biosciences and other 10K+ public comps

Cellectar Biosciences Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 33% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $4.7M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Cellectar Biosciences Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Cellectar Biosciences M&A and Investment Activity

Cellectar Biosciences acquired  XXX companies to date.

Last acquisition by Cellectar Biosciences was  XXXXXXXX, XXXXX XXXXX XXXXXX . Cellectar Biosciences acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Cellectar Biosciences

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Cellectar Biosciences

When was Cellectar Biosciences founded? Cellectar Biosciences was founded in 1996.
Where is Cellectar Biosciences headquartered? Cellectar Biosciences is headquartered in United States of America.
How many employees does Cellectar Biosciences have? As of today, Cellectar Biosciences has 11 employees.
Who is the CEO of Cellectar Biosciences? Cellectar Biosciences's CEO is Mr. James V. Caruso.
Is Cellectar Biosciences publicy listed? Yes, Cellectar Biosciences is a public company listed on NAS.
What is the stock symbol of Cellectar Biosciences? Cellectar Biosciences trades under CLRB ticker.
When did Cellectar Biosciences go public? Cellectar Biosciences went public in 2005.
Who are competitors of Cellectar Biosciences? Similar companies to Cellectar Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Cellectar Biosciences? Cellectar Biosciences's current market cap is $13.6M
Is Cellectar Biosciences profitable? Yes, Cellectar Biosciences is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.